Fawry’s TPA license places it between patients, providers, and payers

Fawry secured a Third-Party Administrator (TPA) licence through a new subsidiary, Treemed TPA, that will “operate as the backbone of Fawry Healthcare,” the company said in a press release last month. The fintech platform has been quietly building toward healthcare administration for several years by acquiring entities in medical services management and launching an ins. company, CEO Ashraf Sabry tells EnterpriseAM.

Behind the new brand: Fawry Healthcare will manage ins. claims, administer provider networks, process digital healthcare payments, and use data analytics for fraud detection and claims leakage prevention. The strategy is one of ecosystem integration rather than a standalone business, Sabry says. “Fawry differentiates between platform services and direct end client products,” he says. “The TPA will work with other ins’ers. Service providers can use our health technology solutions and we can integrate our TPA into their platforms.”

SOUND SMART- A TPA sits between an ins. company/provider and the healthcare system. It doesn’t carry ins. Risk — it manages the program: processing claims, verifying eligibility, running provider networks, and authorizing procedures. The company or provider underwrites while the TPA operates, earning a service fee, not a share of premiums. What makes TPA control significant is the data: a TPA that manages claims sees every transaction between patient, provider, and payer.

The regulatory backdrop

Companies performing TPA functions in Egypt previously operated outside direct Financial Regulatory Authority (FRA) oversight — managing healthcare programs for ins. companies and corporates without being subject to the same rules that govern the ins. companies themselves. A source at the FRA tells EnterpriseAM that this created structural and cumulative problems. Some companies were assuming ins. risk — covering treatment costs directly for companies and unions — without holding the technical reserves required to back those liabilities. Others operated with no binding standards on approval speeds, complaint handling, or data confidentiality. The FRA concluded that bringing TPAs under its supervision was necessary to protect the financial stability of the system and the rights of policyholders, the source tells us.

The new framework was established under the Unified Ins. Law No. 155 of 2024. Under it, a licensed TPA cannot design and sell ins. programs directly to the public or carry financial risk without a licensed ins. company behind it. Disputes are now governed by FRA Board Resolution No. 77 of 2025, which requires companies to establish complaint units and gives policyholders a path to escalate to the FRA directly.

The pricing squeeze

Fawry is entering a sector under acute financial stress. The core problem is a pricing trap the new regulatory framework does not address, TPA operator Tricare ’s Chairman Mohamed Abdelgany tells EnterpriseAM. TPAs are contractually obligated to deliver services at fixed prices for the duration of a contract, while hospitals and laboratories raise their fees mid-year with no regulatory constraint. “I am obligated to deliver the service — but the one selling me the service is the one who raised the price, not me,” Abdelgany tells us. He gives a specific example: a consultation fee at one major hospital rose from EGP 450 to EGP 750 and then to EGP 1.2k within the same contract year. Multiplied across 37k clients, he says, the price difference becomes mns of EGP in losses absorbed entirely by the TPA.

The safety valve that previously allowed TPAs to pass excess costs to clients — known as a stop-loss mechanism — was abolished by the FRA. Abdelgany says the authority has also declined to regulate provider pricing directly on the grounds that hospitals fall under the Health Ministry’s jurisdiction, not the FRA’s. That leaves TPAs caught between fixed-fee contracts and unregulated provider inflation, with no mechanism to recover the difference.

Fawry’s model appears structured to avoid this trap. Fawry’s licence focuses on the technical administration of ins. programs, with pricing risk sitting with ins. companies rather than with Treemed TPA, Abdelgany says. That means Fawry targets administrative service fees while remaining insulated from the provider pricing volatility that is squeezing existing operators. Whether that model solves the sector’s structural cost problem — or simply sidesteps it — is a question the company has not yet answered.

The pitch

The commercial logic starts with a structural problem Sabry has long identified in the local ins. market. Most providers work with a limited network of large hospital groups, leaving a wide segment of smaller clinics and pharmacies outside the insured system — too administratively burdensome to onboard, too slow to pay. Fawry’s pitch is that it can change that by simplifying claims processing and shortening payment cycles. “We believe we will enable ins’ers to expand their offering to other market segments,” Sabry says.

Sehetak Fawry, the company’s earlier limited medical ins. product, was the proof of concept. It reached more than 700k beneficiaries by leveraging Fawry’s existing base — but it hit a ceiling, Sabry says. “The TPA will bring a more sophisticated offering to scale,” he adds, without elaborating on what specifically constrained the earlier product.

Where it gets consequential

Controlling utilization is central to the TPA’s value proposition. Medical ins. costs in Egypt are rising y-o-y, Sabry says, and without systems capable of managing clinical operations and controlling service costs, expanding coverage is economically unsustainable. “The healthcare system, once you create an ins. model, sees overuse, misuse, and abuse. The TPA is accountable for making sure spending is rational,” Islam Anan, professor of health economics and epidemiology at Misr International University, tells us.

In practice, that means Treemed TPA will have systems that flag — and in some cases block — certain prescriptions or procedures automatically, though Sabry is careful to draw a line. “Ins. policies, medications, and procedures all have rules that reflect both financial constraints and use of the right medication based on diagnosis, gender, and customer profile,” he tells us. “We use local and international databases to make sure there is no abuse, but the final decision is made by the doctor unless it clearly violates a clear rule.” His examples: adult medication cannot be prescribed to a child; a dose cannot exceed a treatment period; if two medications share an active ingredient, ins. policy determines which brand is covered.

The FRA source confirms that licensed TPAs have discretion to build fraud detection models and design medical approval protocols, provided they do not conflict with the terms of FRA-approved ins. policies and are not used to arbitrarily delay or withhold services from beneficiaries. The FRA views TPAs as active market participants — not neutral conduits — that negotiate with provider networks and generate data that ins. companies use to price medical products, the source says.

The conflict of interest question is harder to dismiss. Fawry is simultaneously building an ins. company, a TPA, and a payments platform — meaning it could be underwriting a policy, administering its claims, and processing its payments for the same patient. Sabry says this is a known tension Fawry has navigated before. “Since inception, Fawry clearly differentiates between being a platform serving the ecosystem and having its own clients. It is difficult and challenging, but we have done this successfully with many financial organisations that use our platform to facilitate business with their clients, while Fawry can have competing products directly offered to Fawry clients.” The analogy holds in fintech, but whether it holds in healthcare — where the stakes of a denied claim are categorically different from a declined payment — is a question the company has not yet had to answer at scale.

On data, Sabry says fraud detection is a standard TPA service offered to all ins. companies, including Fawry’s own microins. arm. He did not address whether patient data generated through Treemed TPA flows back into Fawry’s broader consumer and payments platform. This is the central unresolved question of the architecture, and it will matter more as the ecosystem grows.

What UHI does to all of this

The country’s universal health ins. rollout is the structural tailwind behind all of this. Anan argues UHI will not shrink the private ins. Market — it will expand it. Once basic state coverage exists, the private market will be selling supplementary products to a newly ins.-literate population. “It won’t just be 10% of the population covered by private schemes,” Anan says. “It could reach 40% of Egyptians subscribing to private ins. companies.” The FRA source describes the authority’s goal as moving the market from fragmented, ungoverned practice toward a system subject to periodic reporting, strict governance, and standardized medical codes and claims forms across the sector.

Anan is measured on whether that adds up to monopoly risk. “Technology alone does not create a monopoly. It depends on whether you have a strong health policy, whether the regulator is controlling and governing the system,” he says. “With a strong health policy, nobody can monopolize the system,” Anan adds.

What’s next: Sabry did not give specific targets for providers signed, lives covered, or market share over the next three years. For now, Treemed TPA is the licensed entity. What it becomes depends on how quickly Fawry builds out its network, whether ins. companies are willing to hand program administration to a fintech company with no prior healthcare operating history, and whether the platform vs. competitor distinction Sabry describes holds up once Fawry Healthcare is large enough that the difference matters.